Approximately 6,000 senior citizens' lives could be saved annually by a new vaccine.
The United States has made progress towards preventing tens of thousands of cases of respiratory syncytial virus (RSV).
Recent findings from the pharmaceutical company GSK demonstrate that its RSV vaccination
The findings are the first RSV vaccine findings to be supported and validated by the peer review process
According to research, just 7 out of 12,467 participants who received the vaccine's single dosage
"This is undoubtedly an important achievement," Dean L. Winslow, MD, professor of medicine
Moreover, RSV vaccinations are being created for high-risk newborns and expectant moms.
CLICK FOR MORE